Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases

Scarlet Therapeutics develops engineered red blood cells designed to treat metabolic diseases and address shortages in rare blood supplies. Scarlet Therapeutics uses synthetic biology and proprietary cell line technology to create lab-grown red blood cells that can be manufactured at scale for therapeutic and transfusion use.